
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 4 March 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 3MB, 220 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
“Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes”, BMJ Open Diabetes Res Care, vol. 5, p. e000400, 2017.
, “Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti-diabetic drugs”, Pharmacoepidemiol Drug Saf, 2017.
“Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs”, BMC Pharmacol Toxicol, vol. 16, p. 8, 2015.
“Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN)”, Pharmacoepidemiol Drug Saf, vol. 24, pp. 999-1003, 2015.
“Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury”, Pharmacoepidemiol Drug Saf, vol. 21, pp. 1155-72, 2012.
, “Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies”, Pharmacoepidemiol Drug Saf, vol. 21, pp. 1202-15, 2012.
, “Antidiabetic action of bezafibrate in a large observational database”, Diabetes Care, vol. 32, pp. 547-51, 2009.
, “Immunosuppressant medications and mortality in inflammatory bowel disease”, Am J Gastroenterol, vol. 103, pp. 1428-35; quiz 1436, 2008.
, “The risk of mortality in patients with psoriasis: results from a population-based study”, Arch Dermatol, vol. 143, pp. 1493-9, 2007.
, “Is there cross-reactivity between penicillins and cephalosporins?”, Am J Med, vol. 119, pp. 354.e11-9, 2006.
, “The relationship between time since registration and measured incidence rates in the General Practice Research Database”, Pharmacoepidemiol Drug Saf, vol. 14, pp. 443-51, 2005.
, “Comparative cardiac safety of low-dose thioridazine and low-dose haloperidol”, Br J Clin Pharmacol, vol. 58, pp. 81-7, 2004.
, “Represcription of penicillin after allergic-like events”, J Allergy Clin Immunol, vol. 113, pp. 764-70, 2004.
, “Seasonal variation in flares of inflammatory bowel disease”, Gastroenterology, vol. 126, pp. 665-73, 2004.
, “Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics”, N Engl J Med, vol. 349, pp. 1628-35, 2003.
, “The incidence and prevalence of pressure ulcers among elderly patients in general medical practice”, Ann Epidemiol, vol. 12, pp. 321-5, 2002.
, “Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease”, Pharmacoepidemiol Drug Saf, vol. 11, pp. 211-8, 2002.
, “Inflammatory bowel disease is not associated with an increased risk of lymphoma”, Gastroenterology, vol. 121, pp. 1080-7, 2001.
,